7-1 thumbs down - more testing needed, page-23

Just heard conference call and this is not bad news, its a gross overreaction. CXS were surprised that the committee were asked to vote on this specific question, and not efficacy and safety. In fact Greg said that the cancer specialist on the board was VERY positive on the efficacy and Greg was of the opinion that this is not a problem for approval. In short he stated that this is just another step in the approval process and the market has got it WRONG. They meet on April 9 to discuss the outlines concerning the validation of the diagnostic testing. Greg said that all testing they did was "sequenced" which is universally agreed as being the appropriate method. He also said that they wont be asked to trail again. This is all GOOD news, this stock is a bargain